SEC Form 10-Q filed by CG Oncology Inc.
$CGON
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/11/2025 | $70.00 | Outperform | Wedbush |
| 11/24/2025 | Buy | Truist | |
| 10/8/2025 | $90.00 | Buy | Guggenheim |
| 8/19/2025 | $55.00 | Overweight | Piper Sandler |
| 7/10/2025 | $40.00 | Buy | Goldman |
| 5/2/2025 | $41.00 | Overweight | Analyst |
| 4/16/2025 | $23.00 | Sector Perform | Scotiabank |
| 1/7/2025 | Buy | TD Cowen |
144 - CG Oncology, Inc. (0001991792) (Subject)
8-K - CG Oncology, Inc. (0001991792) (Filer)
8-K - CG Oncology, Inc. (0001991792) (Filer)
Wedbush initiated coverage of CG Oncology with a rating of Outperform and set a new price target of $70.00
Truist initiated coverage of CG Oncology with a rating of Buy
Guggenheim initiated coverage of CG Oncology with a rating of Buy and set a new price target of $90.00
4 - CG Oncology, Inc. (0001991792) (Issuer)
3 - CG Oncology, Inc. (0001991792) (Issuer)
3 - CG Oncology, Inc. (0001991792) (Issuer)
- PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy for intermediate-risk NMIBC now expected in 1H 2026, nearly one year ahead of schedule - First randomized registrational trial to evaluate an investigational therapy in intermediate-risk NMIBC IRVINE, Calif., Jan. 09, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ:CGON) today announced an expedited timeline for the topline data readout now expected in the first half of 2026 for the Phase 3 PIVOT-006 clinical trial comparing adjuvant intravesical cretostimogene grenadenorepvec versus surveillance in patients with intermediate-risk non-muscle invasive bladder cancer (IR NMIBC). PIVOT-006 is the first Phase 3 randomi
IRVINE, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ:CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced that Arthur Kuan, Chairman & Chief Executive Officer, and Ambaw Bellete, President & Chief Operating Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026, at 8:15 am PT / 11:15 am ET. The conference is taking place at the Westin St. Francis San Francisco, California. Interested parties may access the live audio webcast for this conference from the Investor Relations section of the
Two applicants will each receive a Grant of $50,000 to support the development of outstanding clinical cancer research to improve the treatment of NMIBCApplications for the fellowship are due on February 27, 2026 SCHAUMBURG, Ill. and IRVINE, Calif., Dec. 18, 2025 (GLOBE NEWSWIRE) -- The Society of Urologic Oncology Clinical Trials Consortium (SUO-CTC), a national alliance of leading academic and community based uro-oncologists, and CG Oncology, Inc. (NASDAQ:CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced the second annual CG-SUO-CTC NMIBC Rese
4 - CG Oncology, Inc. (0001991792) (Issuer)
4/A - CG Oncology, Inc. (0001991792) (Issuer)
- Appoints Accomplished Life Sciences Executive Christina Rossi to its Board of Directors - IRVINE, Calif., Nov. 26, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ:CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced the appointment of Christina Rossi to its Board of Directors. Additionally, Simone Song, Senior Partner, ORI Capital, has resigned from the Board effective November 22, 2025. "We are at a critical juncture in CG Oncology's history with our recent BLA initiation for cretostimogene. Now we are laying the foundation for a successful
USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 18, 2025 /PRNewswire/ -- USA News Group News Commentary – According to a recent report in Newsweek, more Americans younger than 50 are getting cancer. In fact, the report cites a recent study from the National Institutes of Health (NIH), which found that between 2010 and 2019, more than 2 million Americans aged 15 to 49 were diagnosed with cancer, with early-onset cases rising significantly in 14 different cancer types, including breast, colorectal, and kidney cancers. The dire statistics from the study come at a time where Bloomberg has recently reported on the skyrocketing costs of cancer drugs,
SC 13G/A - CG Oncology, Inc. (0001991792) (Subject)
SC 13G/A - CG Oncology, Inc. (0001991792) (Subject)
SC 13G - CG Oncology, Inc. (0001991792) (Subject)
- Robust 24-month complete response rate of 42.3% by K-M for cretostimogene monotherapy in BOND-003 Cohort C – - 58.3% of patients showed durable complete responses by K-M at 24 months – - 97.3% of all treated patients remained free from progression to MIBC at 24 months– - 91.6% of responders remained cystectomy-free at 24 months – - No Grade 3 or greater treatment-related adverse events or deaths reported – - Strong initial Cohort P data reported 90.5% high-grade recurrence-free survival at 3 and 9 months by K-M – - Company will host a conference call and webcast at 8 a.m. EDT on Monday, April 28, 2025 - IRVINE, Calif., April 26, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ:C
IRVINE, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ:CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced it will host a conference call and live webcast at 8:00 am ET on April 28, 2025, to discuss results from the Phase 3 BOND-003 trial of cretostimogene monotherapy in high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) to be presented on April 26, 2025, at a Plenary Session at the American Urological Association (AUA) Annual Meeting in Las Vegas, Nevada. Individuals can access the webcast via the link on
- Cretostimogene Monotherapy Demonstrated Sustained, Durable Complete Responses in High-Risk Bacillus Calmette Guérin (BCG)-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) - - Initiated CORE-008 Clinical Trial of Cretostimogene Monotherapy in High-Risk BCG-Naïve (Cohort A) and BCG-Exposed (Cohort B) NMIBC - - Late-Breaking Clinical and First Translational Data from BOND-003 Cohort C Presented at the 40th Annual European Association of Urology Congress - - Completed Oversubscribed $238 Million Follow-on Public Equity Offering that Extends Expected Runway into the First Half of 2028 - IRVINE, Calif., March 28, 2025 (GLOBE NEWS